Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | APAF1 | O14727 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7367989 | 0.87 | ALDH1A1 (0.46) | KDM4EMEN1KMT2AAPAF1CASP6 | |
| SCHEMBL2948723 | 0.79 | GAA (0.53) | KDM4EMEN1KMT2AALDH1A1TSHR | |
| SCHEMBL9199287 | 0.79 | LMNA (0.40) | KDM4EMEN1KMT2AAPAF1CASP6 | |
| SCHEMBL652922 | 0.77 | MAPK1 (0.39) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL9299928 | 0.77 | LMNA (0.60) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL515776 | 0.76 | ALDH1A1 (0.54) | KDM4EMEN1KMT2AAPAF1CASP6 | |
| SCHEMBL60160 | 0.76 | PNP (0.47) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL10432471 | 0.75 | HSD17B10 (0.49) | KDM4EMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL8359284 | 0.73 | PDE1A (0.39) | ALDH1A1LMNACYP3A4MAPTTSHR | |
| SCHEMBL29015257 | 0.72 | KDM4E (0.34) | KDM4EMEN1KMT2AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 511 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111759828-A | Composition and application thereof in treating and/or preventing dementia | 许悦郎 | 2020-10-13 | — | — | CN | claimed |
| US-20160274087-A1 | SCREENING ASSAY FOR AGENTS THAT INFLUENCE BETA CELL NUMBER AND/OR PHENOTYPE | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2016-09-22 | — | — | US | claimed |
| EP-3066468-A1 | SCREENING ASSAY FOR AGENTS THAT INFLUENCE BETA CELL NUMBER AND/OR PHENOTYPE | Vrije Universiteit Brussel (BE) | 2016-09-14 | — | — | EP | claimed |
| WO-2015067744-A1 | SCREENING ASSAY FOR AGENTS THAT INFLUENCE BETA CELL NUMBER AND/OR PHENOTYPE | VRIJE UNIVERSITEIT BRUSSEL (BE) | 2015-05-14 | — | — | WO | claimed |
| US-4337254-A | ANTICOAGULANTS COMPRISING A PROSTACYCLIN AND A PHOSPHODIESTERASE INHIBITOR; PREVENTING LOWERING OF BLOOD PRESSURE | BURROUGHS WELLCOME CO. (US) | 1982-06-29 | — | — | US | claimed |
| US-12605361-B2 | Carboxylated psilocybin derivatives and methods of using | Enveric Biosciences Canada Inc. (CA) | 2026-04-21 | — | — | US | disclosed |
| US-20260103442-A1 | AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2026-04-16 | — | — | US | disclosed |
| US-12514882-B2 | Faecalibacterium prausnitzii strain EB-FPDK11 and use thereof | ENTEROBIOME INC. (KR) | 2026-01-06 | — | — | US | disclosed |
| US-20250352512-A2 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2025-11-20 | — | — | US | disclosed |
| US-20250352513-A2 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | ENVERIC BIOSCIENCES CANADA INC (CA) | 2025-11-20 | — | — | US | disclosed |
| EP-4630067-A1 | 3D FAT TISSUE STRUCTURE, PRODUCED USING LIGHT-BASED STRUCTURING CURING, FOR USE AS A BREAST IMPLANT | Cellbricks GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| US-20250304643-A1 | PEPTIDE DUAL AGONISTS OF GIPR AND GLP2R | BAINAN BIOTECH APS (DK) | 2025-10-02 | — | — | US | disclosed |
| EP-0567562-B1 | METHODS FOR DETECTING GLUCAGON ANTAGONISTS | ZYMOGENETICS INC (US) | 1996-03-13 | — | — | EP | disclosed |
| EP-0658170-A1 | GLUCAGON ANTAGONISTS AND METHODS FOR DETECTING GLUCAGON ANTAGONISTS | ZYMOGENETICS, INC. (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5408037-A | Antidiabetic agents; genetic engineering | ZYMOGENETICS, INC. (US) | 1995-04-18 | — | — | US | disclosed |
| WO-1994014427-A2 | USE OF SKYRIN AND ANALOGUES FOR THE TREATMENT OF DIABETES MELLITUS AND PROCESS FOR THEIR PREPARATION | ZYMOGENETICS, INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| US-5310759-A | Methods of protecting and preserving connective and support tissues | BOCKMAN RICHARD S | 1994-05-10 | — | — | US | disclosed |
| WO-1994005699-A1 | GLUCAGON ANTAGONISTS AND METHODS FOR DETECTING GLUCAGON ANTAGONISTS | ZYMOGENETICS, INC. (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0567562-A1 | METHODS FOR DETECTING GLUCAGON ANTAGONISTS. | ZYMOGENETICS INC (US) | 1993-11-03 | — | — | EP | disclosed |
| WO-1992012998-A1 | METHODS FOR DETECTING GLUCAGON ANTAGONISTS | ZYMOGENETICS, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250352512-A2 | C4-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | HTR4, HTR2C, HTR3C | KDM4E 707/4885MEN1 635/4885KMT2A 1177/4885 |
| US-20260103442-A1 | AMINATED PSILOCYBIN DERIVATIVES AND METHODS OF USING | HTR2C, CNR2, HTR2B | KDM4E 958/4885MEN1 4004/4885KMT2A 1298/4885 |
| US-20250352513-A2 | SALTS OF C4-CARBOXYLIC ACID- AND C4-CARBONOTHIOATE-SUBSTITUTED TRYPTAMINE DERIVATIVES AND METHODS OF USING | SLC6A4, HTR4, SLC6A3 | KDM4E 2668/4885MEN1 933/4885KMT2A 1482/4885 |
| US-12605361-B2 | Carboxylated psilocybin derivatives and methods of using | CNR2, HTR2B, HTR2C | KDM4E 358/4885MEN1 4314/4885KMT2A 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.